Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00495144 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors
A Phase 1 study of Hypoxia and Tumors, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 129
- Enrollment target
- 7
- Study locations
NCT00495144: Completed Phase 1 study of Hypoxia and Tumors, sponsored by Threshold Pharmaceuticals.
NCT00495144 is a Phase 1 study of Hypoxia and Tumors that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 129 participants, below the 3,114-participant average among 39 other Hypoxia trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00495144, a Phase 1 study of Hypoxia and Tumors, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 129 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors. The study is designed to establish the safety including the maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of TH-302.
Interventions
- DRUG TH-302
Study Locations (7)
Arizona
- TGen Drug Development Services - Scottsdale
- Mayo Clinic Arizona - Scottsdale
California
- St. Mary's Medical Center - San Francisco
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Minnesota
- Mayo Clinic Rochester - Rochester
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- Mary Crowley Cancer Research Centers - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2007-06 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
What the finished NCT00495144 record still lists
NCT00495144 is an interventional study that assigns participants to a tested intervention. The registered 129 participants enrollment target is mid-sized for trials with a published cap, below the 3,114-participant average among 39 other Hypoxia trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hypoxia appearing as the primary indexed condition, and to 1 intervention - of which TH-302 is the first listed.
NCT00495144 lists 7 locations in 6 states (Arizona, California, Indiana).
Frequently Asked Questions
What is clinical trial NCT00495144 about?
NCT00495144 is a clinical study titled "A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors". This is a phase I, multi-center, open-label, dose-escalation study of TH-302 in patients with advanced solid tumors. TH-302 is a hypoxia activated product designed to exploit the hypoxic nature of tumors. The study is designed to establish the safety including the maximum tolerated dose, the pharmac...
What is the current status of trial NCT00495144?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 129 participants. The study started on 2007-06. Estimated completion is 2012-06.
What conditions does trial NCT00495144 study?
This clinical trial studies the following conditions: Hypoxia, Tumors.
What interventions are being tested in trial NCT00495144?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT00495144?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00495144 being conducted?
This trial has 7 study locations across Arizona, California, Indiana, Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00495144's enrollment target sits among peer trials
129 9th of 39 higher than 31 of 39 other Hypoxia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude
RECRUITING · NA
-
Intravenous Iron Effects on Performance at High Altitude
RECRUITING · Phase 4
-
End-Tidal Oxygen for Intubation in the Emergency Department
RECRUITING · NA
-
Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
RECRUITING · Phase 2
-
Pulse Oximeter Accuracy in Healthy Humans During Hypoxia
RECRUITING
-
Impact of Early Aging and Menopause on the Vascular Responses to Hypoxia
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03619850 · 129 participants · Phase 3
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
- NCT05704361 · 129 participants · Phase 1
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
- NCT05919849 · 129 participants · Phase 1
Supporting Parents in Affirming Their Children's Experiences of Stigma
- NCT06313749 · 129 participants · NA
Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia